MX2016003082A - Terapia que se dirige a proteinas polipopsis adenomatosa coli (apc) truncadas. - Google Patents

Terapia que se dirige a proteinas polipopsis adenomatosa coli (apc) truncadas.

Info

Publication number
MX2016003082A
MX2016003082A MX2016003082A MX2016003082A MX2016003082A MX 2016003082 A MX2016003082 A MX 2016003082A MX 2016003082 A MX2016003082 A MX 2016003082A MX 2016003082 A MX2016003082 A MX 2016003082A MX 2016003082 A MX2016003082 A MX 2016003082A
Authority
MX
Mexico
Prior art keywords
proteins
apc
adenomatous polyposis
polyposis coli
therapeutics targeting
Prior art date
Application number
MX2016003082A
Other languages
English (en)
Inventor
Debrabander Jef
W Shay Jerry
Wang Wentian
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2016003082A publication Critical patent/MX2016003082A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención descrita proporciona compuestos anticáncer de moléculas pequeñas que se dirigen de forma selectiva e inhiben la actividad biológica medible de proteínas APC truncadas, un modelo de Células Epiteliales Colónicas de Humano (HCEC) y composiciones farmacéuticas que comprenden al menos uno de los compuestos anti-cáncer de moléculas pequeñas y un portador farmacéuticamente aceptable.
MX2016003082A 2013-09-10 2014-09-10 Terapia que se dirige a proteinas polipopsis adenomatosa coli (apc) truncadas. MX2016003082A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361875933P 2013-09-10 2013-09-10
US201461930754P 2014-01-23 2014-01-23
PCT/US2014/054987 WO2015038644A2 (en) 2013-09-10 2014-09-10 Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins

Publications (1)

Publication Number Publication Date
MX2016003082A true MX2016003082A (es) 2016-09-13

Family

ID=52666505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003082A MX2016003082A (es) 2013-09-10 2014-09-10 Terapia que se dirige a proteinas polipopsis adenomatosa coli (apc) truncadas.

Country Status (16)

Country Link
US (2) US9856233B2 (es)
EP (1) EP3044218B1 (es)
JP (1) JP6506291B2 (es)
KR (2) KR102300576B1 (es)
CN (1) CN105873913B (es)
AU (2) AU2014318821B2 (es)
BR (1) BR112016005252A2 (es)
CA (1) CA2924062C (es)
DK (1) DK3044218T3 (es)
ES (1) ES2811090T3 (es)
HK (1) HK1224291A1 (es)
MX (1) MX2016003082A (es)
RU (1) RU2727516C2 (es)
SG (1) SG11201601850YA (es)
WO (1) WO2015038644A2 (es)
ZA (2) ZA201601798B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2727516C2 (ru) 2013-09-10 2020-07-22 Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Терапевтические средства, нацеленные на укороченные белки аденоматозного полипоза толстого кишечника (арс)
US10082496B2 (en) 2014-09-10 2018-09-25 Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
EP3322417B1 (en) * 2015-07-15 2023-08-23 The Board of Regents of The University of Texas System Targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
DK3426654T3 (en) 2016-03-09 2022-01-03 Harvard College Direct palladium-catalyzed aromatic fluorination
CA3031818A1 (en) * 2016-07-27 2018-02-01 Case Western Reserve University Compounds and methods of promoting myelination
WO2019126702A1 (en) 2017-12-22 2019-06-27 Case Western Reserve University Compounds for promoting myelination
CN108250111B (zh) * 2018-01-15 2020-04-28 华南理工大学 一种双受体有机发光小分子材料及其制备方法和应用
EP3890715A4 (en) * 2018-12-04 2023-03-29 The Board Of Regents Of The University Of Texas System THERAPEUTIC AGENTS TARGETING ADENOMATOCOLIC POLYPOSIS (APC) MUTANT FOR THE TREATMENT OF CANCER
CN113624665A (zh) * 2021-07-30 2021-11-09 中国药科大学 一种抗肿瘤候选化合物在治疗结直肠癌药物中的应用及测定方法
WO2024020156A1 (en) * 2022-07-22 2024-01-25 Biogen Ma Inc. Emopamil-binding protein inhibitors and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
ZW21483A1 (en) 1982-10-08 1985-05-08 Glaxo Group Ltd Device for administering medicaments to patients
NO166268C (no) 1985-07-30 1991-07-03 Glaxo Group Ltd Innretning for administrering av medikamenter til pasienter.
JPH0667926B2 (ja) * 1985-11-12 1994-08-31 旭化成工業株式会社 環状のイソキノリンスルホンアミド誘導体
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
JP2001172257A (ja) 1999-10-05 2001-06-26 Fujisawa Pharmaceut Co Ltd 有機スルホンアミド化合物
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
CA2364178C (en) 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
WO2002070469A2 (en) * 2001-03-05 2002-09-12 Icos Corporation Selective pde3b inhibitors and use of the same in therapy
DE10155684A1 (de) * 2001-11-13 2003-05-22 Bayer Ag Thiazolharnstoffe
WO2004069828A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
EP1758884A2 (en) * 2004-05-20 2007-03-07 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
US7759339B2 (en) * 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2006134481A1 (en) * 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
WO2007115805A2 (en) * 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Aurora kinase inhibitors
AU2007234843B2 (en) * 2006-04-07 2013-07-11 Methylgene Inc. Inhibitors of histone deacetylase
US8603465B1 (en) * 2006-08-07 2013-12-10 Merck Sharp & Dohme, Corp. Methods for treatment of polyposis
WO2009032703A1 (en) 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2283160A4 (en) 2008-05-07 2012-01-04 Wintherix Llc METHOD FOR IDENTIFYING WNT SIGNALING MODULATING COMPOUNDS IN CANCER CELLS
WO2009144719A2 (en) 2008-05-27 2009-12-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of killing cells and use of same in prevention and treatment of cancer
TW201028421A (en) * 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
CA2874998A1 (en) 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
JP2015508644A (ja) 2012-02-08 2015-03-23 インサイト ジェネティクス インコーポレイテッド 癌の診断および治療のためのｒｏｓ１の融合体に関する方法および組成物
US20130330761A1 (en) 2012-06-12 2013-12-12 Celcuity, LLC Whole cell assays and methods
RU2727516C2 (ru) 2013-09-10 2020-07-22 Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Терапевтические средства, нацеленные на укороченные белки аденоматозного полипоза толстого кишечника (арс)

Also Published As

Publication number Publication date
WO2015038644A3 (en) 2015-05-14
CA2924062C (en) 2019-05-14
AU2018202898A1 (en) 2018-05-17
JP6506291B2 (ja) 2019-04-24
AU2014318821A1 (en) 2016-04-14
HK1224291A1 (zh) 2017-08-18
DK3044218T3 (da) 2020-07-27
ZA201601798B (en) 2022-05-25
CA2924062A1 (en) 2015-03-19
US10577344B2 (en) 2020-03-03
KR20160049014A (ko) 2016-05-04
EP3044218A4 (en) 2017-02-22
SG11201601850YA (en) 2016-04-28
WO2015038644A2 (en) 2015-03-19
ES2811090T3 (es) 2021-03-10
KR20180011890A (ko) 2018-02-02
CN105873913A (zh) 2016-08-17
US20190135776A1 (en) 2019-05-09
ZA201805172B (en) 2019-08-28
EP3044218A2 (en) 2016-07-20
ES2811090T8 (es) 2022-09-29
US20150232444A1 (en) 2015-08-20
AU2014318821B2 (en) 2018-04-19
CN105873913B (zh) 2019-12-03
RU2727516C2 (ru) 2020-07-22
KR102300576B1 (ko) 2021-09-08
JP2016534140A (ja) 2016-11-04
EP3044218B1 (en) 2020-05-27
US9856233B2 (en) 2018-01-02
BR112016005252A2 (pt) 2017-09-12
KR101824230B1 (ko) 2018-01-31
RU2016113279A (ru) 2017-10-16

Similar Documents

Publication Publication Date Title
MX2016003082A (es) Terapia que se dirige a proteinas polipopsis adenomatosa coli (apc) truncadas.
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
MY195009A (en) Cellular Targeted Active Ingredient Delivery System
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
EP3583218A4 (en) TARGETED ACTIVE SUBSTANCE RELEASE ON LIGAND PAYLOAD BASIS FOR CELL THERAPY
PH12016500420A1 (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
MX2016005395A (es) Formulacion estable de insulina glulisina.
EA201692318A1 (ru) Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
AU2012347200A8 (en) Tablet capable of combatting misuse by injection
MX2017014641A (es) Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
MX2018005358A (es) Comprimido de dosis alta que contiene mesalazina optimizado.
EA201490862A1 (ru) Осмотически активная система вагинальной доставки
MY183068A (en) Pharmaceutical formulation comprising antibody
EP3534987A4 (en) ADJUSTABLE-DOSE DRUG DELIVERY SYSTEM
MX341642B (es) Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.
WO2015100370A3 (en) Sustained release depot formulations of therapeutic proteins, and uses thereof
EP3036260A4 (en) Bruton's tyrosine kinase as anti-cancer drug target
PH12017501979A1 (en) Pharmaceutical compound
EP3053601A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER CONTAINING THE CYB5R3 GENE OR PROTEIN AS AN ACTIVE SUBSTANCE
IN2013MU03370A (es)